Physician profile
James Mark Seratt
NPI 1568453918
$443.73
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.76 · 2020: $54.04 · 2021: $155 · 2022: $64.81 · 2023: $55.71 · 2024: $53.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $108.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $75.70 | 2019-2021 | |
| Lilly USA, LLC | $73.39 | 2019-2024 | Jardiance |
| Pfizer INC. | $50.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.96 | 2020-2023 | Jardiance |
| Glaxosmithkline, LLC. | $25.04 | 2019-2021 | |
| Kyowa Kirin, INC. | $23.06 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.35 | 2022 | |
| Sumitomo Pharma America, INC. | $22.23 | 2023 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.24 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.31 | 2024 | Fanapt |
| Novo Nordisk INC | $15.00 | 2021 | |
| Amgen INC. | $14.68 | 2019 | |
| Abbott Laboratories | $13.31 | 2022 | |
| Astellas Pharma US INC | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Seratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.